Kidney Health Is Heart Health

0:00 · Opening

A patient hears that her kidney blood test is fine. But the urine albumin test has never been done. What does that leave unanswered?

Welcome to HEART RESERVE Clinical Conversations. I’m Lisa Zahakos, a physician assistant and founder of HEART RESERVE.

In this episode, we’ll follow Denise with an incomplete assessment, Rosa with residual kidney and cardiovascular risk, and Carol with a safety result that changes the next step. These are fictional teaching cases for clinicians.

You can listen straight through, or use the chapters to return to a case. I’ll ask you to consider a few decisions and then walk through the reasoning. The activity page has the objectives, references and online questions.

0:38 · Case 1 · Denise: the missing kidney test

Let’s work through the first case.

Denise, 49, is a fictional patient with type 2 diabetes diagnosed three years ago after a remote history of gestational diabetes. She works shifts and helps care for her mother. Today her A one C is 6.7 percent, blood pressure is 132/80 millimeters of mercury, and E G F R is 78 milliliters per minute per one point seven three square meters. The chart contains several metabolic panels but no quantitative urine albumin-to-creatinine ratio, or U A C R, during the past year. She says, “I thought the blood test checked my kidneys.”

The immediate teaching problem is incomplete assessment. Her reassuring glucose result and preserved filtration should not close the visit. Before going further, consider what is missing. Denise's pregnancy history belongs in the longitudinal health record, but this encounter is about the kidney-to-heart connection now.

Two measurements answer different questions.

E G F R estimates filtration; U A C R measures albumin relative to urine creatinine. The 2026 American Diabetes Association standard calls for both at least annually in all people with type 2 diabetes. In established chronic kidney disease, monitoring becomes more frequent according to risk. A normal-looking filtration estimate cannot substitute for the urine measure.

Use the first result to decide what needs verification. A U A C R below 30 milligrams per gram is category A1; 30 to 299 is A2; 300 or more is A3. Interpret these with the filtration category and clinical setting. A single abnormal value does not by itself establish chronic disease. chronic kidney disease requires an abnormality of kidney structure or function lasting at least three months. Do not apply a chronic label to an acute change without evaluating what happened.

The result comes back.

Denise's U A C R is 86 milligrams per gram. The nurse learns that she had urinary burning when the sample was taken. The next task is to assess and treat the symptomatic problem as clinically indicated, then arrange confirmation. Infection, recent strenuous exercise, menstruation and other transient influences can raise urinary albumin. American Diabetes Association describes confirmation with two abnormal samples among three collected over three to six months. The clinician must also establish chronicity and interpret the whole record.

Here is the decision. Denise has E G F R 78 and no recorded U A C R. What should the team do next?

Pause here if you would like a moment to think it through.

The best next step in this case is: Complete the urine albumin assessment and review both kidney measures.

Both measures are needed; neither A one C nor past pregnancy history substitutes for the missing assessment.

This does not mean ignoring the result for six months. Confirm that Denise receives the message, determine an appropriate repeat collection date and document the clinician responsible for interpreting it. If she has acute illness, a rapid deterioration in renal function or other concerning findings, a routine confirmation schedule is inadequate. Clinical urgency always comes first.

Make the missing test easy to complete.

Denise can attend laboratory appointments only before an early shift. Ask whether a same-site collection or a coordinated morning visit is feasible. Explain the purpose in plain language: “The blood test and urine test tell us different parts of the kidney story. We need both before we can put the results together.” This original counseling example supports understanding without promising that an abnormal result will disappear.

A practical office workflow is to check for both results before a diabetes review, flag an uncompleted order, and route the result to a named inbox owner. These are proposed implementation choices, not measured results of this activity. The team should adapt them to its own staffing and laboratory arrangements. A new electronic order is not success if the sample is never collected.

Follow-up over the next six months.

In the fictional follow-up, the infection has resolved. Two properly collected U A C R samples are 74 and 71 milligrams per gram, obtained more than three months apart within a six-month confirmation period, with no identified transient cause and stable E G F R. Denise now needs evaluation of cause, risk and management, rather than a message saying only “mildly abnormal.” The clinical team reviews blood pressure, medications, cardiovascular risk, symptoms and the trajectory. Diabetes can coexist with other kidney disease; atypical features should not automatically be attributed to diabetes.

The transfer lesson is a sequence: identify the missing measurement, interpret the result, establish persistence and ensure someone acts. Notice the difference between the medical question, what does the result mean?, and the operational question, who will make sure it is reviewed? Both matter to a woman whose health information is spread across several clinicians.

Here is the decision. Her first U A C R of 86 milligrams per gram was collected during urinary symptoms. Which plan best closes this step?

Pause here if you would like a moment to think it through.

The best next step in this case is: Assess the symptomatic problem, arrange confirmation and name the result-reviewing clinician.

Interpret the clinical context, establish persistence and make the result actionable.

Here is what to carry into the next visit. Find the E G F R and U A C R, with dates. Check transient influences and establish chronicity. Name the clinician who will review the repeat result.

6:01 · Case 2 · Rosa: protection beyond A1C

Now let’s change the situation.

Rosa, 61, is a fictional woman with type 2 diabetes, obesity and confirmed chronic kidney disease. Over six months her E G F R has remained near 46 milliliters per minute per one point seven three square meters and U A C R near 420 milligrams per gram. Potassium is 4.6 milliequivalents per liter. She takes metformin and a tolerated angiotensin receptor blocker; medication reconciliation finds no S G L T 2 inhibitor, G L P 1 receptor agonist or finerenone. Her A one C is 6.5 percent, at her individualized goal. She asks, “Why add another medicine when the diabetes number is good?”

Rosa's question is reasonable. Begin by explaining the problem the proposed treatment is intended to address. The decision is about kidney disease progression and cardiovascular events as well as glucose control. It is not an automatic instruction to add every available drug on the same day. Establish her current regimen, symptoms, volume status, comorbidities, previous adverse effects, medication access and preferences before selecting a plan.

Separate the glucose goal from organ protection.

Published guidance recommends an S G L T 2 inhibitor with demonstrated benefit for appropriate people with type 2 diabetes and chronic kidney disease, with initiation generally supported from E G F R 20 milliliters per minute per one point seven three square meters; the exact product label and indication still matter. G L P 1 therapy with demonstrated benefit also has a role. The presence of albuminuric chronic kidney disease should trigger a broader discussion even when A one C is at target.

For Rosa, review blood pressure control and whether her angiotensin receptor blocker is appropriately optimized and tolerated. An ACE inhibitor and angiotensin receptor blocker should not be combined. Check kidney function, potassium and symptoms when these therapies are initiated or intensified. Treating lipids, smoking, physical activity, nutrition and other cardiovascular risks remains part of comprehensive care; a new drug does not replace that work.

Review the trial before making the claim.

EMPA-KIDNEY enrolled a broad chronic kidney disease population, including people without diabetes. Its primary outcome combined kidney disease progression with cardiovascular death. DAPA C K D also studied chronic kidney disease with and without diabetes, but used different entry criteria and a different composite endpoint. These trials support treatment decisions in suitable populations; they are not a head-to-head comparison of the two medicines.

FLOW studied once-weekly injectable semaglutide in people with type 2 diabetes and chronic kidney disease. Its primary composite included major kidney disease events and kidney-related or cardiovascular death. It provides outcomes evidence for the studied regimen and population. Do not transfer that result automatically to every G L P 1 medicine, formulation or obesity population. The current Ozempic injection label includes a chronic kidney disease-related risk-reduction indication in adults with type 2 diabetes.

Here is the decision. Rosa asks why organ-protective treatment is being discussed when A one C is at target. Which reply is best?

Pause here if you would like a moment to think it through.

The best next step in this case is: Kidney and cardiovascular outcomes are separate treatment considerations; review proven benefit and individual safety.

Explain the clinical goal and match evidence to the person.

FIDELITY pooled the finerenone outcome trials in type 2 diabetes and chronic kidney disease on background renin, angiotensin system blockade. It reported cardiovascular and kidney benefits. Finerenone therefore enters a discussion about persistent residual risk, together with its potassium and kidney-function requirements. It is not simply an interchangeable blood pressure tablet.

A useful new study is still a specific study.

CONFIDENCE compared finerenone plus empagliflozin with each alone in people with type 2 diabetes, chronic kidney disease and albuminuria already receiving renin, angiotensin system inhibition. Its primary outcome was relative U A C R change at 180 days. Combination therapy reduced U A C R more than either monotherapy. That is a biomarker finding, not proof from this trial of fewer kidney failures or cardiovascular deaths versus each component. It can inform a conversation without becoming a claim the study did not test.

Compare each study’s population, endpoint and clinical implication. Ask whether each result answers Rosa’s clinical question, and distinguish a change in albuminuria from a reduction in clinical events.

Shared decisions include practical constraints.

Rosa reports recurrent genital yeast infections, worries about medication cost and does not want several unexplained changes at once. An S G L T 2 discussion includes the risk of genital infection, volume depletion, and ketoacidosis, which can occur without marked hyperglycemia. She needs individualized sick-day and procedural instructions and a clear route to clinical advice. For empagliflozin, the label specifies withholding for at least three days, if possible, before surgery or procedures with prolonged fasting. Resume according to clinical stability and oral intake guidance.

If considering injectable semaglutide, review its contraindications, including personal or family medullary thyroid carcinoma or multiple endocrine neoplasia type 2, gastrointestinal tolerability, pancreatitis warnings, retinopathy context, and dehydration-related renal concerns. These are reasons to assess and counsel carefully, not reasons to assume all patients face the same balance of benefit and harm. Use the current full prescribing information for the complete evaluation.

The worked communication example is: “Your glucose goal is one part of the plan. Your kidney results show another risk we can address. Let us compare what each option has been shown to do, what might make it difficult for you, and what follow-up it needs.” Discuss affordable options and assistance through appropriate channels without steering the clinical decision toward a sponsor. Record an agreed next action and review date; the vignette alone cannot determine Rosa's final prescription.

Here is the decision. A colleague describes CONFIDENCE as proof that the combination prevents more kidney failures than either drug alone. How should you respond?

Pause here if you would like a moment to think it through.

The best next step in this case is: Clarify that the primary endpoint was U A C R change, not comparative kidney-failure events.

Randomization supports the measured comparison; it does not change the endpoint into one that was not tested.

Here is what to carry into the next visit. State the organ-risk goal separately from the glucose goal. Match population, endpoint, product and indication. Discuss safety, cost, preferences and monitoring together.

12:40 · Case 3 · Carol: a plan that reaches the next visit

For the third case, the follow-up plan becomes especially important.

Carol, 67, is a fictional woman with type 2 diabetes, hypertension and persistent albuminuria. Her E G F R is 38 milliliters per minute per one point seven three square meters and U A C R is 560 milligrams per gram. A proposed finerenone prescription is awaiting review. Today's potassium is 5.3 milliequivalents per liter. She takes an angiotensin receptor blocker, sometimes uses an over-the-counter anti-inflammatory medicine, and recently began a salt substitute after reading that it might help blood pressure. She feels well and has a specialist appointment scheduled in eight weeks.

The teaching task is to stop the prescription from moving ahead without review and to establish who is responsible while the referral is pending. Do not infer the cause of the potassium result from the vignette. The clinician needs to assess the specimen, trend, symptoms, medications, supplements and current health. A severely abnormal result or concerning symptoms would change the urgency; this exercise does not provide a universal outpatient hyperkalemia protocol.

Safety changes the next action.

The finerenone US label states that treatment should not be initiated if potassium is above 5.0 milliequivalents per liter. Kidney function also affects eligibility and dosing. Review interactions, including strong C Y P 3 A 4 inhibitors, and contraindications such as adrenal insufficiency. The label's four-week potassium check after initiation does not justify starting in Carol's current situation or waiting four weeks to address her existing abnormality.

After appropriate assessment and correction, if finerenone is selected and initiation criteria are met, arrange potassium monitoring at four weeks after starting and after dose adjustment, with subsequent testing as clinically indicated. For ACE inhibitor or angiotensin receptor blocker initiation or dose escalation, KDIGO recommends checking blood pressure, creatinine and potassium within two to four weeks, adjusted to the clinical context. These are different medication-specific follow-up decisions; do not replace them with a generic annual diabetes visit.

The medication list includes what the patient buys.

Ask Carol to bring or photograph the labels of nonprescription medicines and salt substitutes. Some contain potassium, and kidney function and concomitant therapy affect the advice. Avoid a blanket instruction either to eliminate every potassium-containing food or to use a potassium salt substitute freely. Coordinate individualized dietary review when appropriate. The purpose is a workable plan based on the actual product and laboratory findings, not a generic food restriction.

Carol explains that she is afraid of “bothering” the office. Give her the name of the team handling the next result and a specific contact method. Ask what she would do if she develops new symptoms, cannot obtain the laboratory test, or receives conflicting instructions. Teach-back can reveal that a plan written clearly in the chart was not understood at home. These are original examples of care coordination for discussion and adaptation.

Here is the decision. Carol has potassium 5.3 before proposed finerenone. What is the next action?

Pause here if you would like a moment to think it through.

The best next step in this case is: Do not initiate; clinically assess the result and contributing factors.

The initiation restriction applies now. Review urgency based on the complete clinical situation.

Referral does not transfer care automatically.

Progressively rising albuminuria, falling E G F R, uncertainty about cause, difficult electrolyte or blood pressure management, and advanced chronic kidney disease can prompt nephrology involvement. Active urinary sediment, rapid deterioration or other atypical findings deserve evaluation rather than assuming uncomplicated diabetic kidney disease. Determine the appropriate urgency and send the trends and current medication list with the referral.

The primary team should confirm whether the receiving service accepted the referral and whether the appointment timing is appropriate. Until responsibilities are explicitly agreed, retain an interim owner for current abnormalities and medication decisions. A specialist's name in an electronic order does not establish that the specialist has seen the patient, reviewed the result or agreed to manage it.

A worked follow-up plan.

For this teaching example, the prescribing clinician pauses the proposed finerenone initiation, reviews potassium and contributing factors promptly, determines repeat testing and urgency, and communicates the interim plan to Carol. The team checks referral acceptance, sends the renal trend and reconciled medication list, and records who will respond to results before the specialist visit. The final clinical timetable depends on the full assessment. Consider how that plan would work in your own setting.

At a subsequent visit, Carol reports that she understood the test was needed but could not find transportation. The response should address the barrier and re-evaluate whether delay changes urgency. A missed test is not automatically refusal. A feasible local arrangement, an explained purpose and an agreed result-review process are components of care, not administrative extras.

Carry the kidney story into the heart story.

The summary passed to the next clinician should include the kidney measurements and dates, current treatment and tolerance, cardiovascular conditions, the unresolved issue and who is acting next. Include reproductive history when clinically relevant, but do not allow it to crowd out today's priorities. This is the distinctive HEART RESERVE connection: women's histories stay visible while care becomes specific, coordinated and actionable.

Here is the decision. Which element is most important to add to Carol’s pending referral?

Pause here if you would like a moment to think it through.

The best next step in this case is: An agreed interim care owner, result-review plan and patient contact route.

Make clinical responsibility explicit until an accepted handoff occurs. This is the activity’s proposed application of guideline-based follow-up.

Here is what to carry into the next visit. Check the safety result before starting or changing therapy. Record test, date, reviewer and patient contact route. Confirm referral acceptance and retain interim responsibility.

18:46 · Take it into practice

Before you go, bring the three cases back to one question: what will you do differently at the next visit?

Use both kidney measures, match evidence to the patient, and treat monitoring and follow-up as part of the therapy.

You’ll find the source references, transcript and clinical resources beside this episode. To record your answers and complete the learning activity, return to the activity page for the questions and brief evaluation.

This has been HEART RESERVE Clinical Conversations. I’m Lisa Zahakos. Thank you for listening.